There is much interest in the potential of using cell-free DNA (cfDNA) to follow tumor evolution and response to therapy over time. 1, 2 Recently, targeted next-generation sequencing (NGS) of cfDNA has become the first multiplexed form of liquid biopsy to be commercially available in the clinical setting.
2,3 The goal of this study was to determine the reliability and potential utility of this technology in the clinical treatment of patients with metastatic prostate cancer, investigating the congruence of reported mutations in 2 independent platforms.
Methods | From January 2017 to July 2017 samples from 40 patients with metastatic prostate cancer were collected at the same time serially via a single blood draw and shipped overnight to 2 different Clinical Laboratory Improvement Amendments (CLIA)-licensed, College of American Pathologistsaccredited laboratories for cfDNA next-generation sequencing following the instructions of each vendor. Guardant360 (Guardant Health, Inc) panel includes 73 genes with complete exon sequencing for 19 cancer genes, critical exons in 54 genes and amplifications (18 genes),
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Each column represents 1 patient with 1 or more alterations reported in at least 1 platform. Only alterations in genes purportedly covered by both commercial gene panels were considered. Exome coverage for each gene in the sequencing panel differs between platforms. Congruence among tests was assessed on confirmation of exome coverage with the counterpart platform for each alteration in the study. cfDNA indicates cell-free DNA; G, results using Guardant360 (Guardant Health, Inc); P, results using PlasmaSELECT (Personal Genome Diagnostics, Inc), PSA, prostate-specific antigen.
fusions (6 genes), and indels (23 genes) with high clinical sensitivity rates (85% in stage III/IV solid tumors) and ultrahigh specificity (>99.9%).
2,4
PlasmaSELECT (Personal Genome Diagnostics, Inc) consists of a 64-gene panel with a reported sensitivity for singlebase mutations and indels of 99.4% and a per base specificity greater than 99.9%.
2,5 Analytic sensitivity for indels and point mutations is reported to be down to 0.1% mutant allele fraction in Guardant360 and 0.5% in PlasmaSELECT.
2,4,5
Prostate-specific antigen (PSA) baseline serum levels were determined within 30 days of the genetic test for 90% of patients, mean time from PSA blood work to the cfDNA test was 16 days (range, 0-115 days). Written informed consent was obtained in accordance with Johns Hopkins University School of Medicine institutional review board (IRB) guidelines, and this study received IRB approval.
Results | The genetic alterations determined by cfDNA testing and baseline PSA serum levels in our cohort of patients with metastatic prostate cancer are summarized in Figure 1 . Participants were classified as complete congruence, 0 alterations if neither platform detected any alteration, (9/40 [22.5%]) ( Figure 2) .
For the study of congruence among tests, only genetic alterations in genes purportedly covered by both platforms were considered (42 genes), thus patients with 1 or more alterations demonstrated by at least 1 platform (31/40 [77.5%]) whose all cfDNA alterations were covered by only 1 of the tests were excluded (6/40 [15%]). Out of the 42 genes in the overlapping panel, a total of 25 genes had reported alterations in our cohort (60%); TP53 (n = 10), ATM (n = 6), ALK, BRCA1, and BRCA2 (n = 5) were the most common.
Exome coverage for every gene in each sequencing panel differs between platforms. Congruence among tests was assessed on confirmation of exome coverage in the counterpart platform for each alteration reported, excluding those alterations reported whose chromosomic location was not covered by the other platform.
There were 25 of 40 (62.5%) patients with alterations in the overlapping genes with confirmed coverage. Three (7.5%) of 40 patients had complete congruence with 1 or more alterations, 6 (15%) of 40 had partial congruence, and 16 (40%) of 40 had no congruence. The remaining 15 patients either did not have any reported alteration (complete congruence with 0 alterations, 9/40 [22.5%]) or were not evaluable for patientlevel congruence (6/40 [15%]).
Discussion | Despite the limited sample size, our data show very low congruence for same patient-paired samples in 2 CLIAcertified commercially available tests with self-reported high accuracy, specificity, and sensitivity to specifically detect and quantify tumor-specific alterations. These data cannot determine which test is more accurate but suggest that reported gene alterations will not be the same across different platforms, raising the specter that patients could potentially receive different treatments depending on the cfDNA platform. Insufficient genetic profiling congruence could jeopardize the clinical benefit of personalized medicine. 
Oral Ketamine vs Placebo in Patients With Cancer-Related Neuropathic Pain: A Randomized Clinical Trial
Ketamine hydrochloride is used as an adjuvant treatment for cancer-related neuropathic pain, but evidence of its effectiveness is limited. 1 Findings of a large trial investigating the use of ketamine for general cancer pain were negative, but the population studied did not specifically have neuropathic pain.
2 A randomized trial of oral ketamine for cancer-related neuropathic pain has been called for, 3 and the present trial addresses that need.
1
Methods | A multicenter, double-blind randomized clinical trial of oral ketamine vs placebo was conducted in the United Kingdom cities of Edinburgh, Glasgow, Nottingham, and Lancashire in adults with cancer-related neuropathic pain, which was defined using set criteria (Leeds Assessment of Neuropathic Symptoms and Signs). Patients had previously been treated with adjuvant analgesics for neuropathic pain, which had been ineffective or suboptimal. Preexisting analgesia was continued throughout the trial. Patients were centrally randomized using minimization, then ketamine or placebo was titrated across 2 weeks to an effective and tolerable dosage (Figure) . : 2007-002080-27) , and participants provided written informed consent. The primary end point was duration of analgesic benefit, defined as an improvement of 5 points or more in the index pain score (using the Sensory Component of the Short Form McGill Pain Questionnaire), compared with the baseline score during the 16 days of receiving a stable dosage of ketamine or placebo. Patients in whom titration failed were considered to have a duration of 0 days. Maintenance of analgesic benefit was considered to have failed in patients whose opioid dosage increased during this time. Secondary end points included mean and worst pain; mood (Hospital Anxiety and Depression Score, a self-administered anxiety and depression screening tool for use in nonpsychiatric patients. The tool has 14 items, which focus on the emotional and cognitive aspects of each aspect. Each item is scored from 0 to 3 for a combined maximum of 21 for each aspect, with higher scores reflecting a higher symptom load); mean change in global distress in the last 24 hours (National Comprehensive Cancer Network Distress Thermometer, which uses a scale of 0 to 10, where 0 is no distress and 10 is extreme distress); quality of life (EuroQoL Thermometer, a patient-rated assessment of present quality of life comprising 5 questions, each assigned a value of 0 to 2 points, with higher values representing better quality of life. The sum of these responses produces a score on a scale of 0 to 10, which is then translated into a scale of 0 to 100); and serious adverse events (National Cancer Institute, Common Toxicity Criteria for Adverse Events version 3.0, which provides clinicians with descriptive terminology for reporting adverse events. Each adverse event is graded on a scale of 1 to 5, with higher grades representing greater severity).
An intention-to-treat approach was used, with a sample size of 107 patients per arm providing 80% or greater power to detect an improvement in the duration of analgesic benefit while receiving ketamine corresponding to a 20% increase in patients in whom analgesic benefit was maintained at 16 days (maximum hazard ratio [HR], 0.58). To compare duration of analgesic benefit, we used Cox proportional hazards regression with a confirmatory log-rank test. Secondary end points were analyzed using parametric and nonparametric methods. Quality of life data were analyzed by calculating the mean of the area under the curve over the time in the study after adjusting for the baseline value. All P values are 2-tailed, and P < .05 was statistically significant. Statistical analyses were performed using SPSS version 22.0 for Windows (IBM).
